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Ductal carcinoma in situ: to treat or not to treat,
that is the question
Maartje van Seijen1, Esther H. Lips1, Alastair M. Thompson2, Serena Nik-Zainal3, Andrew Futreal4, E. Shelley Hwang5, Ellen Verschuur6,
Joanna Lane7, Jos Jonkers1,8, Daniel W. Rea9 and Jelle Wesseling1,10,11 on behalf of the PRECISION team
Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent upon detection by population-based
breast cancer screening programmes. Currently, all DCIS lesions are treated, and treatment comprises either mastectomy or breast-
conserving surgery supplemented with radiotherapy. However, most DCIS lesions remain indolent. Difficulty in discerning harmless
lesions from potentially invasive ones can lead to overtreatment of this condition in many patients. To counter overtreatment and
to transform clinical practice, a global, comprehensive and multidisciplinary collaboration is required. Here we review the incidence
of DCIS, the perception of risk for developing invasive breast cancer, the current treatment options and the known molecular
aspects of progression. Further research is needed to gain new insights for improved diagnosis and management of DCIS, and this
is integrated in the PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment Now) initiative. This international effort
will seek to determine which DCISs require treatment and prevent the consequences of overtreatment on the lives of many women
affected by DCIS.
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BACKGROUND
Ductal carcinoma in situ (DCIS) was rarely diagnosed before
the advent of breast screening, yet it now accounts for 25% of
detected ‘breast cancers’. Over 60,000 women are diagnosed
with DCIS each year in the USA,1,2 >7000 in the UK3 and >2500
in the Netherlands.4 DCIS is a proliferation of neoplastic
luminal cells that are confined to the ductolobular system of
the breast. If DCIS progresses to invasive breast cancer, DCIS
cells penetrate the ductal basement membrane and invade the
surrounding parenchyma. Individual lesions differ in aspects of
the disease: presentation, histology, progression, and genetic
features.5,6 Despite being pre- or non-invasive, DCIS is often
regarded as an early form of (Stage 0) breast cancer. Therefore,
conventional management includes mastectomy or breast-
conserving surgery supplemented with radiotherapy; in some
countries, adjuvant endocrine therapy is added. Regrettably,
current therapeutic approaches result in overtreatment of
some women with DCIS (Box 1). The Marmot Report in 2012
recognised the burden of overtreatment to women’s wellbeing.7
In effect, women with DCIS are labelled as ‘cancer patients’, with
concomitant anxiety and negative impact on their lives, despite
the fact that most DCIS lesions will probably never progress to
invasive breast cancer. Owing to the uncertainty regarding
which lesions run the risk of progression to invasive cancer,
current risk perceptions are misleading and consequently bias
the dialogue between clinicians and women diagnosed with
DCIS, resulting in overtreatment for some, and potentially
many, women.
Improving the management and treatment of DCIS presents a
central challenge: distinguishing indolent, harmless DCIS lesions
from potentially hazardous ones. This poses a fundamental
question to address: ‘Is cancer always cancer?’. To answer this
question, we need to adopt an interdisciplinary and translational
approach, merging fields of epidemiology, molecular biology,
clinical research and psychosocial studies. How low does the risk
need to be to refrain from treating DCIS? What are the prognostic
markers and read-outs we can rely on? How do we frame and
communicate the risks involved?
In this review, we describe the current approaches to
diagnosing DCIS, the perception of the risk of developing invasive
breast carcinoma, the treatment options available following a
diagnosis and a current knowledge of the progression of DCIS,
before outlining future endeavours and the need for an integrated
approach that blends clinical and patient insights with scientific
advances.
DCIS INCIDENCE
The number of women diagnosed with DCIS over the past few
decades largely follows the introduction of population-based
breast cancer screening.8–12 The European standardised rate of
in situ lesions has increased four-fold, from 4.90 per 100,000
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women in 1989 (accounting for 4.5% of all diagnoses registered as
breast cancer) to 20.68 in 2011 (accounting for 12.8% of all
diagnoses registered as breast cancer; www.cijfersoverkanker.nl).
Of all in situ breast lesions reported, 80% are DCIS.12,13 Never-
theless, the incidence of mortality from early-stage breast cancer
has not decreased concurrently with DCIS detection and treat-
ment, indicating that managing DCIS does not reduce breast-
cancer-specific mortality and therefore could be considered as
overtreatment.8,11 A review of autopsies in women of all ages
revealed a median prevalence of 8.9% (range 0–14.7%). For
woman aged >40 years, this prevalence was 7–39%,14 whereas
breast cancer is diagnosed in only 1% of women in the same age
range.13 These data suggest that a large number of women might
have an undetected source of DCIS that will never become
symptomatic.
CURRENT DIAGNOSIS AND IMAGING
DCIS is usually straightforward to detect by mammography
because of its association with calcifications; the proliferation of
cells itself is not visible on the mammogram. However, as only
75% of all DCIS lesions contain calcifications,15 a substantial
percentage of DCIS lesions will not be detected by mammogra-
phy, implying that some lesions might be mammographically
occult or that the diameter of the area containing calcifications
underestimates the extent of DCIS.16,17 This suggests that DCIS
might be left behind following breast-conserving treatment in a
proportion of cases.
After detection, the lesion is classified by the pathologist by
histological features as low, medium or high grade, which is
assumed to correspond to the level of aggressiveness. Surpris-
ingly, many grading systems exist.18 An agreement on classifica-
tion was reached during a consensus meeting in the USA where
consensus was reached to include nuclear grade, presence of
necrosis, cell polarisation and architectural patterns in the
pathology report.19,20 Some studies showed a slight tendency
for high-grade DCIS to progress to invasive breast cancer,21 but
others demonstrated that grade is not significantly associated
with the risk of local invasive recurrence.22,23 Greater consistency
in grading could result in more certainty about the association of
morphology with progression and outcome. In addition, as grade
is not a perfect discriminator for progression risk, other risk
discriminators, such as molecular biomarkers, are examined
(discussed later in ‘Molecular, cellular and microenvironmental
aspects’).
PERCEPTION OF RISK
Generally, patients diagnosed with DCIS have an excellent long-
term breast-cancer-specific survival of around 98% after 10 years
of follow-up24–27 and a normal life expectancy.27 However, a
consensus in the medical community is lacking on how to
effectively communicate to patients about DCIS and the
associated risk of development into invasive cancer.28 It is
essential to be aware of the fact that if the lower-grade DCIS
(considered as the lower-risk lesions) progresses into invasive
breast cancer, this will often be the lower-grade, slow-growing
and early-detectable invasive disease, with excellent prognosis.
Because both diagnosis and treatment of the condition can
have a profound psychosocial impact on a woman’s life, adequate
perception of risk by both health professionals and patients is
important in determining the appropriate modalities of treatment.
Despite an excellent prognosis and normal life-expectancy,
women diagnosed with DCIS experience stress and anxiety.29
Studies report that most women with DCIS (and early-stage breast
cancer) have little knowledge and inaccurate perceptions of the
risk of disease progression, and this misperception is associated
with psychological distress.30–36 Women with DCIS make sub-
stantial changes to their behaviour after diagnosis, including
smoking cessation and decreasing the use of postmenopausal
hormones.37
Similar to progression rates for DCIS, classic lobular carcinoma
in situ (LCIS) confers a risk of 1–2% per year to develop into
invasive disease.38,39 First-line treatment for LCIS usually comprises
active surveillance; unlike DCIS, doctors and patients accept the
concept of active surveillance to monitor for progression of LCIS
before administering any aggressive treatment. The need for
effective doctor–patient communication is therefore essential for
patients to understand the risk of recurrence.40,41 According to
Kim et al.,36 women in whom DCIS was detected experienced high
decisional conflict in treatment options and were not satisfied
with the information provided to them. The development of a
prediction tool could help to classify patients into risk groups and
provide accurate guidance to patients, as well as healthcare
professionals, in their choice of an appropriate treatment option.42
Nowadays, such a tool is even more important, as patients
increasingly wish to engage in shared decision making about their
disease.
TREATMENT OF DCIS
Surgery and radiation therapy
Currently, breast-conserving treatment for DCIS is frequently
recommended. A mastectomy is advised if the DCIS is too
extensive to allow breast conservation.43 According to Thompson
et al.,21 the recurrence rates (for both invasive and in situ) with 5
years median follow-up are 0.8% after mastectomy, 4.1% after
breast-conserving surgery followed by radiotherapy and 7.2%
after breast-conserving surgery alone. According to Elshof et al.,22
invasive recurrence rates are 1.9, 8.8 and 15.4%, respectively, after
10 years median follow-up. The 15-year cumulative incidence in
the National Surgical Adjuvant Breast and Bowel Project 17
(NSABP17) trial of patients with clear margins is 19.4% after breast-
conserving surgery alone and 8.9% after breast-conserving
surgery followed by radiotherapy.44 Four randomised clinical trials
have been performed to investigate the role of radiotherapy in
breast-conserving treatment for DCIS after complete local
excision of the lesion. In a meta-analysis, these trials show a
50% reduction in the risk of local recurrences (for both in situ
and invasive) after radiotherapy.45 Radiotherapy was reported to
be effective in reducing the risk of local recurrence in all analysed
subgroups according to age, clinical presentation, grade and type
of DCIS.
Adding radiotherapy to breast-conserving treatment reduces
local recurrence rates but does not influence overall survival or
breast-cancer-specific survival.27,45,46 The added value of conduct-
ing a sentinel node biopsy procedure is uncertain. In general, such
a procedure is done with mastectomy for DCIS (since there is no
opportunity to perform a subsequent sentinel node biopsy) or
Box 1: Consequences of overdiagnosis in DCIS: Impact of DCIS
on a woman’s life
The diagnosis of DCIS labels women as being at risk for invasive breast cancer.
Despite the good prognosis and normal life-expectancy, women diagnosed with
DCIS may experience substantial psychological distress29 and overestimate the
implications of a DCIS diagnosis.34,35,92 Comorbidity of surgery and prior
depression have been reported as important factors related to worse quality of
life in these women.29 Critical questions yet to be answered include: (i) Can the
way in which a diagnosis for DCIS is communicated be improved? (ii) Can the
labelling effects of a diagnosis of DCIS be mitigated, while ensuring adequate
follow-up of these high-risk women? And, finally, (iii) what is the impact on
quality of life for active surveillance of women diagnosed with low-grade DCIS?
Addressing these questions requires central involvement of patient voices to
improve clarity not only for patients but also for healthcare providers about the
implications and risks of a diagnosis of DCIS.93
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where there is a high suspicion for invasive disease even where
DCIS alone is present in the preoperative biopsy.47,48
A recent study based on an analysis of data from the
American Cancer Registry of >100,000 women diagnosed with
DCIS suggests that aggressive treatment might not be necessary
to save lives.24,49 A retrospective Surveillance, Epidemiology,
and End Results (SEER) study demonstrated for the first time that
patients with low-grade DCIS had the same overall survival and
breast-cancer-specific survival rates with or without surgery.49
These findings prompted the breast healthcare community to
explore innovative studies that could circumvent the need for
harsh therapeutic intervention for treating an indolent
condition.24,49
Endocrine therapy
Owing to the side effects of hormonal therapy and ambiguous
results from clinical trials, postmenopausal women with DCIS are
rarely treated with endocrine therapy in many countries. In
addition, the notion of systemic treatment for a localised disease
with an excellent outcome is perceived as being
counterintuitive.21,50 Two randomised clinical trials have inves-
tigated the role of tamoxifen – a drug that inhibits the oestrogen
receptor (ER) – versus placebo in DCIS.44,51 The risk of
subsequent invasive ipsilateral breast cancer was found to be
reduced by tamoxifen in the NSABP trial44; the UK, Australia and
New Zealand (UK/ANZ) DCIS trial demonstrated a reduction in
recurrent DCIS but not in invasive breast cancer.51 Tamoxifen
administration did not influence overall survival in either trial52
and appeared to be more effective at reducing the incidence of
new breast events in patients who did not receive radiotherapy
in the NSABP trial.51 Yet, a non-significant reduction in the
incidence of new breast events was seen in the prospective
series from the UK, independent of whether the patients
received radiotherapy or not.53 Furthermore, to prevent one
recurrence, 15 patients would need to be treated (the number
needed to treat).52 In terms of efficacy, tamoxifen and
anastrozole (an aromatase inhibitor) are comparable, and the
percentage of women who reported side effects were 91% and
93% for anastrozole and tamoxifen, respectively. Although
anastrozole administration more often causes side effects such
as musculoskeletal pain, hypercholesterolaemia and strokes,
tamoxifen is associated with muscle spasm, deep vein throm-
bosis and the development of gynaecological symptoms and
gynaecological cancers.54 In the USA, the uptake of endocrine
treatment is higher than in other countries, and nearly half of all
ER positive patients are treated by additional adjuvant
tamoxifen treatment, indicating a lack of consensus on the
added value of this treatment.55
Active surveillance
To address the question whether some patients with DCIS are
overtreated, a group of patients not treated with conventional
therapies should be studied. A prospective study with long-term
follow-up is the only way to gain confidence regarding the
natural course of DCIS, and therefore the potential need for
interventions. Recently, three clinical trials (LORIS (United King-
dom, NCT02766881),56 COMET (United States of America,
NCT02926911)57,58 and LORD (The Netherlands, NCT02492607))59
have opened to randomise patients with low-risk DCIS between
active surveillance and standard treatment. Lower grades of DCIS
are enrolled (grade 1 and/or grade 2 with limitations depending
on the trial). Patients receive annual mammography (in COMET
biannual mammography) in the active surveillance arm to monitor
the lesions. Patients in the control arm will get conventional
treatment (surgery often supplemented with radiotherapy). The
primary outcome assesses whether active surveillance is non-
inferior to surgery in terms of ipsilateral invasive breast-cancer-
free survival56 (LORIS), ipsilateral invasive breast-cancer-free
percentage at 2 years (COMET)57 or at 10 years (LORD).59 Because
the primary outcomes of the trials are based on the occurrence of
invasive disease during follow-up, it is essential to exclude an
invasive component at the time of enrolment. Missed invasive
disease at DCIS diagnosis is reported up to 26%.60 However,
Grimm et al. found that, among trial-eligible patients, there was
upstaging of 6, 7 and 10% for COMET, LORIS and LORD trials,
respectively, compared with a general upstaging of 17% at the
time of surgery for preoperatively diagnosed DCIS of all types.61
All trials include only pure DCIS with the use of multiple biopsies,
additional biopsies in extended lesions and vacuum-assisted
(large volume) biopsies.
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Potentially all cells can develop to DCIS
and IDC in parallel
Combination of molecular features of all cells within the duct
give rise to invasive properties with the same phenotype
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All individual cells in the DCIS duct accumulate
different genetic features. Only a specific profile
is able to invade
Multiple clones have the ability to escape the duct and
to become invasive
Fig. 1 Overview of models showing four different theories of progression from ductal carcinoma in situ to invasive breast cancer
Ductal carcinoma in situ: to treat or not to treat, that is the question
M van Seijen et al.
287
FROM DCIS TO INVASIVE BREAST CANCER
Proposed mechanisms for the development of invasive breast
cancer
Although the natural course of the intraductal process is
unknown, DCIS is considered to be a non-obligate precursor of
invasive breast cancer. Four evolutionary models have been
proposed to describe the progression of DCIS into invasive breast
cancer (Fig. 1).
The first model is the independent lineage model. On the
basis of mathematical simulations of the observed frequencies of
the histological grade of DCIS and the histological grade of
invasive disease in the same biopsy sample, Sontag et al.
proposed that in situ and invasive cell populations arise from
different cell lineages and develop in parallel and independently
of each other.62–64 In support of this theory, Narod et al.65 state
that small clusters of cancer cells with metastatic ability spread
concomitantly through various routes to different organs and can
therefore give rise to DCIS, invasive breast cancer and metastatic
deposits simultaneously. Recent studies elucidating molecular
differences between DCIS and invasive breast cancer further
support the relevance of this model.66
The convergent phenotype model proposes that different
genotypes of DCIS could lead to invasive breast cancer of the
same phenotype. Furthermore, this model assumes that all the
cells within the DCIS duct have the same genetic aberrations but
that the combination of aberrations could differ between ducts
(within the same DCIS lesion).67,68 Hernandez et al. demonstrated
similarity in the genomic profiles of DCIS and invasive breast
cancer in the majority of the matched pairs. However, in some
cases, DCIS and adjacent invasive breast cancer differ in copy
number and gene mutations, supporting the notion that, at least
in some cases, progression is driven by specific clones leading to
the same phenotype.69
In the evolutionary bottleneck model, individual cells within a
duct are considered to accumulate different genetic aberrations;
however, only a subpopulation of cells with a specific genetic
profile is able to overcome an evolutionary bottleneck and invade
into the adjacent tissue.63,64,68 This bottleneck model is supported
by studies that report high genetic concordance between in situ
and invasive lesions in addition to some differences between DCIS
and invasive disease.70
In the multiclonal invasion model, multiple clones have the
ability to escape from the ducts and co-migrate into the
adjacent tissues to establish invasive carcinomas63,64 Casasent
et al. demonstrated, using single-cell sequencing, that most
mutations and copy number aberrations evolved within the
ducts prior to the process of invasion. Shifts in clonal
frequencies were observed, suggesting that some genotypes
are more invasive than others. The same subclones were present
in both in situ and in invasive regions with no additional copy
number aberrations acquired during invasion and few invasion-
specific mutations. These findings are, however, limited by their
small sample size and comparison of contemporaneous DCIS
and invasive disease.63
These putative models illustrate the potential complexity of the
invasion process in DCIS and indicate that indolent lesions might
become invasive via a combination of more than one of the
proposed mechanisms.6
Molecular, cellular and microenvironmental aspects
Many studies have focussed on identifying molecular markers of
the invasive process and recent studies69–72 have linked mutations
in PIK3CA, TP53 and GATA3 genes with aggressive DCIS; TP53
mutations were reported to be exclusively associated with high-
grade DCIS.71,72 However, the requirement for fresh tissue and
large amounts of DNA for whole-exome or genome sequencing
has limited the extent of studies for determining the landscape of
genetic mutations in DCIS.
Some molecular analyses have shown that pre-invasive lesions
and invasive breast cancer display remarkably similar patterns,73–76
indicating a common ancestor77; other groups have found that
progression from DCIS to invasive breast cancer might be driven
by a subset of cells with specific genetic aberrations, implying
contribution to tumour initiation.66,77–80 PAM50 is a gene signature
that can classify invasive breast cancer into five intrinsic subtypes
(luminal A, luminal B, HER2-enriched, basal-like and normal-like),
which adds prognostic and predictive information.81 Lesurf et al.74
applied the PAM50 signatures to DCIS and showed substantial
differences between the subtypes, indicating that each
PAM50 subtype undergoes a distinct evolutionary course of
disease progression. Strikingly, their results showed that these
properties, specific for the PAM50 subtypes, reflect changes that
involve the microenvironment rather than molecular changes
specific for epithelial cells. This supports increasing evidence for
the role of the microenvironment in tumour progression and
disease outcome more generally.74 Alcazar et al.82 demonstrated a
switch to a less active tumour immune environment during the
in situ to invasive breast carcinoma transition and identified
immune regulators and genomic alterations that shape tumour
evolution. Their data suggest that the levels of activated CD8+
T cells might predict which DCIS is likely to progress to invasive
disease.82 In patients with invasive breast cancer – particularly
those with triple-negative and HER2-positive subtypes – the
presence of tumour-infiltrating lymphocytes (TILs), especially
higher numbers of CD8+ cells, together with fewer FOXP3+
regulatory T cells, is associated with a better outcome.83
One of the key molecular differences between DCIS and
invasive breast cancer is the prevalence of HER2 amplification:
34% for DCIS84 versus 13% for invasive disease.85 HER2 amplifica-
tion might be a prognostic factor in predicting an in situ
recurrence after DCIS, but it seems not to be predictive for an
invasive recurrence.86 That said, one study with a long follow-up
(mean follow-up >15 years) counterintuitively demonstrated that
HER2 positivity in primary DCIS was associated with a lower risk of
late invasive breast cancer compared with HER2 negativity.87 In
HER2-positive DCIS, TILs are present at higher levels, but an
association with an invasive recurrence risk after DCIS has not
been reported.
A caveat of molecular studies on DCIS is the fact that most
studies examine relatively small series of DCIS lesions with a
contemporaneously adjacent invasive component, instead of a
metachronous (subsequent) invasive lesion developing during
follow-up. Thus these series are inherently biased, because the
majority of the DCIS lesions will never develop an invasive
component. In addition, most studies do not distinguish between
in situ or invasive recurrences after DCIS. Two biomarker-based
assays have been developed for DCIS,88,89 which purport to
predict the benefit of radiotherapy for DCIS. However, the assays
only discriminate between the risk of an in situ versus an invasive
recurrence after DCIS to a limited extent. This difference is
important for the women involved, especially regarding treatment
choices, prognosis and psychosocial impact. Furthermore, intra-
tumoural heterogeneity complicates our understanding of the
relationship between DCIS and its invasive counterpart, as most
studies only analyse a small proportion of an often heterogeneous
lesion or analyse a bulk tissue sample in which small cell
populations are easily overlooked.64 The low number of samples
and lack of longitudinal follow-up data mean that our overall
molecular knowledge of the landscape of changes in DCIS is
limited.
Looking ahead. Uncertainty exists about how DCIS develops, and
global consensus is lacking as to how best to optimally manage
this disease. A better understanding of the biology of DCIS and the
natural course of the disease is required to support patients and
healthcare professionals in making more informed treatment
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decisions, in turn reducing the current overtreatment of DCIS. In
2014, Gierisch et al.90 described and prioritised knowledge gaps of
patients and decision makers with regards to future research of
DCIS for the Patient-Centered Outcomes Research Institute
(PCORI), a private, non-governmental, non-profit, USA-based
institute created by The Patient Protection and Affordable Care
Act of 2010 to ‘help people make informed healthcare decisions,
and improve healthcare delivery and outcomes’. By reviewing the
existing literature and using a forced-ranking prioritisation
method, a list of ten evidence gaps was created (Table 1). Issues
that needed immediate attention include the effective commu-
nication of information about diagnosis and prognosis and
dedicated efforts to fill the knowledge gaps regarding long-term
implications and risks of a diagnosis of DCIS.90
To address these priorities in DCIS, a multidisciplinary approach
with scientific, clinical and patient expertise is needed. Data from
large retrospective cohorts should be integrated with in vitro and
in vivo studies and the results should be validated to transform
clinical practise. To fund such a large multinational consortium,
Cancer Research UK and the Dutch Cancer Society (KWF)
partnered to support the Grand Challenge91 award in 2017, the
PREvent ductal Carcinoma In Situ Invasive Overtreatment Now
(PRECISION) initiative (see Box 2 and Supplementary Material for
more information about PRECISION).
CONCLUSION
Current perceptions of the risk-framing dialogue between
clinicians and women diagnosed with DCIS are currently
resulting in the overdiagnosis and overtreatment of DCIS. The
need to reframe perceptions of risk and to avoid overtreatment
is urgent, as overtreatment leads to physical and emotional
harm for patients and to unnecessary costs for society.
Specifically, knowing when a lesion could be or will not be
life-threatening requires a thorough understanding of the
progression and evolution of DCIS. To this end, initiatives, such
as PRECISION, have been set out to reduce the burden of
Table 1. How PRECISION addresses research needs for DCIS management (adapted from Gierisch et al.90)
Rank Prioritization of research need according to Gierisch
et al.90
Recommended study design by Gierisch
et al.90
Addressed in PRECISION
1 Validate risk-stratification models Meta-analysis or individual patient data
analysis across RCTs or observational study
using existing data sources
Combining retrospective case-control
studies based on nationwide,
population-based cohorts
2 Compare safety and effectiveness of a management
strategy involving no immediate treatment (i.e.
monitoring/observation/active surveillance) versus
immediate treatment with surgery, RT, and/or medical
therapy
Prospective observational study Prospective RCT to test safety of active
surveillance for low-grade DCIS
3 Determine whether safety and effectiveness of DCIS
management strategies differ depending on variations
in clinical, pathologic, and genomic presentations
of DCIS
Meta-analysis or individual patient data
analysis across RCTs or observational study
using existing data sources
Combining results from retrospective
case-control studies and
prospective RCTs
4 Comparative effectiveness of different approaches to
communicating the diagnosis of DCIS to the patient
RCT Evaluation level of being informed,
QoL, and HTA in prospective RCTs
5 Comparative effectiveness of decision-making tools
compared with usual care
RCT Evaluation of prognostic factors, QoL,
and HTA in prospective RCTs
6 Comparative sensitivity and specificity of breast MRI,
mammography, and other preoperative imaging
evaluations for detecting occult invasive breast cancer
Observational study either collecting new
data or using existing data sources
Analysis based on mammograms
collected in prospective RCTs
7 Assess effect of DCIS management strategies on
comorbid conditions
RCT Prospective RCTs
8 Compare safety and effectiveness of partial-breast RT
versus whole-breast RT
RCT Not addressed in this research
proposed
9 Identify most important patient-centered outcomes
for women diagnosed with DCIS
Observational study requiring new data
collection
Prospective RCT for patient-centred
outcomes
10 Assess effect of DCIS management strategies on rates
of invasive cancer
Observational data using existing data Retrospective case-control studies and
prospective RCTs
This Table was adapted from Annals of Internal Medicine, Gierisch, J.M., Myers, E.R., Schmit, K.M., Crowley, M.J., McCrory, D.C., Chatterjee, R., Coeytaux, R.R.,
Kendrick, A. and Sanders, G.D., Prioritization of Research Addressing Management Strategies for Ductal Carcinoma In Situ, Volume 160, Issue 7, Pages 484-491.
Copyright © 2014 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc. DCIS ductal
carcinoma in situ, RT radiotherapy; RCT randomised controlled trial; QoL quality of life, HTA health technology assessment, MRI magnetic resonance imaging,
PRECISION PREvent ductal Carcinoma In Situ Invasive Overtreatment Now
Box 2: The PRECISION initiative
The general aim of the CRUK/KWF Grand Challenge PRECISION Initiative (www.
dcisprecision.org) is to prevent the burden of DCIS overtreatment. ‘PRECISION’ is
the acronym for ‘PREvent ductal Carinoma In Situ Invasive Overtreatment Now’.
PRECISION ultimately aims to develop novel tests that promote informed and
shared decision-making between patients and clinicians, without comprising the
excellent outcomes for DCIS management that are presently achieved. The
PRECISION initiative consists of seven interlinked work packages (WPs). WP1
enables the collection of large tissue resources. These series will be used in
WP2–4 for genomic characterisation to find key drivers (WP2), characterising the
function of the microenvironment in DCIS biology (WP3), and the role of imaging
in DCIS prognosis and outcome (WP4). WP5 comprises functional validation of
the key drivers in in vitro and in vivo models and WP6 will incorporate all the
information obtained in a clinical risk prediction model. The three prospective
studies will be used for overall validation through collection of blood and tissue
samples (WP7). Importantly, patient advocates are actively involved in every part
of the project. Ultimately, all these efforts may contribute to a more balanced
perception of risk regarding non-life-threatening precancerous lesions in general,
reducing anxiety, and preserving quality of life.
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overtreatment of DCIS by gaining deep knowledge about the
biology of DCIS. This knowledge will contribute to informed
decision-making between patients and clinicians, without
compromising the excellent outcomes for DCIS that are
presently achieved. Dealing with this challenge demands an
integrated approach that blends clinical and patient insights
with scientific advances in order to improve the diagnosis,
treatment and management of DCIS. To accomplish this, it is
critical that patient advocates, scientists and clinicians work
together, exemplified by a collaborative patient advocate and
scientist in the PRECISION research team video: https://youtu.
be/aoGSDDto1Gc.
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